Skip to Content

'
Andrew K. Lee, M.D., M.P.H.

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Department of Radiation Physics, Division of Radiation Oncology, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

2000 Harvard School of Public Health, Boston, MA, MPH, Clinical Effectiveness
1999 Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health, Boston, MA, MPH, Clinical Effectiveness
1996 University of Minnesota Medical School, Minneapolis, MN, MD, Medicine
1991 Amherst College, Amherst, MA, BA, Biology

Postgraduate Training

5/2012 Faculty Leadership Academy, Cohort 11: "The Right Stuff", UT MD Anderson Cancer Center, Houston, TX
7/1997-7/2001 Clinical Residency, Radiation Oncology, Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, Dr. Jay Harris, MD
6/1996-6/1997 Medical Internship, Internal Medicine, Good Samaritan Regional Medical Center, Phoenix, AZ, Dr. Alan Leibowitz

Board Certifications

1/2011 American Board of Radiology, Radiation Oncology

Experience/Service

Administrative Appointments/Responsibilities

Director of The Proton Therapy Center, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2008-12/2011
Program Director for Advanced Technologies Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-12/2011
Director, Proton Therapy Fellowship, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2007-present
Faculty Advisor, Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2005-present

Other Appointments/Responsibilities

Clinical Effectiveness Subcommittee Member, UT MD Anderson Cancer Center, Houston, TX, 11/2012-8/2015
Founding member, Proton Therapy Development Group for Genitourinary Malignancies, Houston, TX, 5/2006-present

Institutional Committee Activities

Chair, Proton Therapy Center Clinical Operations, 1/2006-12/2011
Faculty Senator, Faculty Senate, 1/2003-2009

Honors and Awards

2014 2014 Faculty Achievement Award recipient in Patient Care
2013-present Best Doctors in America
2012-present Top Doctors: Southeastern Texas, Castle Connolly Medical LTD
2012-2013 America's Top Doctors, Castle Connolly Medical LTD.
2011-2012 Best Doctors in America 2011-2012, Best Doctors in America
2011-2012 US News Tops Doctors
2010-2011 America's Top Doctors for Cancer!, Castle Connolly Medical LTD.
2007-2008 Guide to America's Top Oncologists, Consumers' Research Council of America

Professional Memberships

Acta Oncologica
Reviewer, 2012-present
American Board of Radiology
Exam writing committee member, 1/2012
ASTRO Annual Meeting Track- GU
Committee, 2013-2014
ASTRO Prostate/GU Resource Panel
Committee, 10/2014-9/2015
ASTRO Prostate/GU Resource Panel
Member, 10/2013-9/2014
The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX
Adjunct Faculty, 11/2010-8/2012

Selected Publications

Peer-Reviewed Original Research Articles

1. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw 12(7):993-8, 7/2014. PMID: 24994920.
2. Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE. Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States. J Urol. e-Pub 6/12/2014. PMID: 24931803.
3. Wootton L, Kudchadker R, Lee A, Beddar S. Real-time in vivo rectal wall dosimetry using plastic scintillation detectors for patients with prostate cancer. Phys Med Biol 59(3):647-60, 2/7/2014. e-Pub 1/17/2014. PMID: 24434775.
4. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 87(5):946-53, 12/1/2013. e-Pub 10/15/2013. PMID: 24139077.
5. Winey B, Shih B, Sahoo N, Lee A, Vapiwala N, Both S. Core Physics Competencies for Proton Therapy Training of Radiation Oncology and Medical Physics Residents and Fellows. International Journal of Radiation Oncology, 11/2013. e-Pub 11/2013.
6. Melancon AD, Lee AK, Kudchadker R, Zhang L, Tucker S, Kuban D, Dong L. Anatomic variation and dosimetric consequences of neoadjuvant hormone therapy before radiation therapy for prostate cancer. Practical Radiation Oncology 3(4):329-36, 10/2013.
7. Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K, Kuban D, Lee A. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. e-Pub 9/17/2013. PMID: 24050892.
8. Li X, Quan EM, Li Y, Pan X, Zhou Y, Wang X, Du W, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A Fully Automated Method for CT-on-Rails-Guided Online Adaptive Planning for Prostate Cancer Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 86(5):835-41, 8/1/2013. e-Pub 5/29/2013. PMID: 23726001.
9. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. e-Pub 8/13/2013. PMID: 23939133.
10. Park PC, Cheung JP, Zhu XR, Lee AK, Sahoo N, Tucker SL, Liu W, Li H, Mohan R, Court LE, Dong L. Statistical Assessment of Proton Treatment Plans under Setup and Range Uncertainties. Int J Radiat Oncol Biol Phys 86(5):1007-13, 8/1/2013. e-Pub 5/18/2013. PMID: 23688812.
11. Pugh TJ, Amos RA, John Baptiste S, Choi S, Nhu Nguyen Q, Ronald Zhu X, Palmer MB, Lee AK. Multifield optimization intensity-modulated proton therapy (MFO-IMPT) for prostate cancer: Robustness analysis through simulation of rotational and translational alignment errors. Med Dosim. e-Pub 6/6/2013. PMID: 23747223.
12. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 12(3):204-9, May-Jun, 5/2013. e-Pub 6/5/2012. PMID: 22673704.
13. Muren L, Rossi C, Hug E, Lee AK, Glimelius B. Establishing and expanding the indications for proton and particle therapy. Acta Oncologica 52:459-462, 3/2013.
14. Li H, Sahoo N, Poenisch F, Suzuki K, Li Y, Li X, Zhang X, Lee AK, Gillin MT, Zhu XR. Use of treatment log files in spot scanning proton therapy as part of patient-specific quality assurance. Med Phys 40(2):021703, 2/2013. PMCID: PMC3555925.
15. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 1/1/2013. e-Pub 10/23/2012. PMID: 23102837.
16. Pair ML, Du W, Rojas HD, Kanke JE, McGuire SE, Lee AK, Kuban DA, Kudchadker RJ. Dosimetric Effects of Weight Loss or Gain During Volumetric-Modulated Arc Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer. Med Dosim 38(3):251-4, 2013. e-Pub 3/26/2013. PMID: 23540491.
17. Rechner LA, Howell RM, Zhang R, Etzel C, Lee AK, Newhauser WD. Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer. Phys Med Biol 57(21):7117-7132, 11/7/2012. e-Pub 10/10/2012. PMCID: PMC3772654.
18. Klein D, Briere TM, Kudchadker R, Archambault L, Beaulieu L, Lee A, Beddar S. In-phantom dose verification of prostate IMRT and VMAT deliveries using plastic scintillation detectors. Radiat Meas 47(10):921-929, 10/1/2012. e-Pub 8/24/2012. PMCID: PMC3501761.
19. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 23(9):2346-52, 9/2012. e-Pub 2/21/2012. PMID: 22357249.
20. Wootton L, Kudchadker R, Beddar A, Lee AK. Effectiveness of a novel gas-release endorectal balloon in the removal of rectal gas for prostate proton radiation therapy. Journal of Applied Clinical Medical Physics 13(5):190-197, 9/2012.
21. Cao W, Lim GJ, Lee A, Li Y, Liu W, Ronald Zhu X, Zhang X. Uncertainty incorporated beam angle optimization for IMPT treatment planning. Med Phys 39(8):5248-56, 8/2012. PMID: 22894449.
22. Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A Comprehensive Comparison of IMRT and VMAT Plan Quality for Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys 83(4):1169-78, 7/15/2012. PMID: 22704703.
23. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era? Int J Radiat Oncol Biol Phys. e-Pub 7/24/2012. PMID: 22836052.
24. Vassiliev ON, Kudchadker RJ, Kuban DA, Frank SJ, Choi S, Nguyen Q, Lee AK. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med 28(3):240-4, 7/2012. e-Pub 8/2011. PMID: 21875820.
25. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer 48(11):1664-71, 7/2012. e-Pub 2/13/2012. PMID: 22336663.
26. Sharp H, Swanson D, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno T, Kuban D, Lee AK, Choi S, Nguyen QN, Hoffman K, McGuire S, Frank S. Screening Colonoscopy Before Prostate Cancer Treatment Can Detect Colorectal Cancers in Asymptomatic Patients and Reduce the Rate of Complications After Brachytherapy. Practical Radiation Oncology 2(3), 7/2012.
27. Pugh TJ, Choi S, Nguyen QN, Gillin M, Zhu R, Palmer M, Lee AK. Proton beam therapy for the treatment of prostate cancer. Practical Radiation Oncology, 5/2012.
28. Archambault L, Poenisch F, Sahoo N, Robertson D, Lee A, Gillin MT, Mohan R, Beddar S. Verification of proton range, position, and intensity in IMPT with a 3D liquid scintillator detector system. Med Phys 39(3):1239-1246, 3/2012. PMCID: PMC3292596.
29. Park PC, Zhu XR, Lee AK, Sahoo N, Melancon AD, Zhang L, Dong L. A Beam-specific Planning Target Volume (PTV) Design for Proton Therapy to Account for Setup and Range Uncertainties. Int J Radiat Oncol Biol Phys 82(2):e329-36, 2/1/2012. e-Pub 6/22/2011. PMCID: PMC3183263.
30. Iyengar P, Levy LB, Choi S, Lee AK, Kuban DA. Toxicity Associated With Postoperative Radiation Therapy for Prostate Cancer. Am J Clin Oncol 34(6):611-8, 12/2011. e-Pub 12/13/2010. PMID: 21150565.
31. Pugh TJ, Lee AK. Role of radiation therapy for the treatment of lymph nodes in urologic malignancies. Urol Clin North Am 38(4):497-506, 11/2011. PMID: 22045180.
32. Zhu XR, Poenisch F, Song X, Johnson JL, Ciangaru G, Taylor MB, Lii M, Martin C, Arjomandy B, Lee AK, Choi S, Nguyen QN, Gillin MT, Sahoo N. Patient-Specific Quality Assurance for Prostate Cancer Patients Receiving Spot Scanning Proton Therapy Using Single-Field Uniform Dose. Int J Radiat Oncol Biol Phys 81(2):552-9, 10/1/2011. e-Pub 2/6/2011. PMID: 21300457.
33. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease? Int J Radiat Oncol Biol Phys 79(5):1310-7, 4/1/2011. e-Pub 5/20/2010. PMID: 20493642.
34. Heng L, Lee AK, Johnson J, Zhu R, Kudchadker R. Characterization of dose impact on IMRT and VMAT from couch attenuation for two Varian couches. Journal of Applied Clinical Medical Physics 12(3). e-Pub 3/2011.
35. Choi S, Lee AK. Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf 3(3):107-119, 2011. e-Pub 12/22/2011. PMCID: PMC3264425.
36. Cheung J, Kudchadker RJ, Zhu XR, Lee AK, Newhauser WD. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer. Phys Med Biol 55(23):7135-47, 12/7/2010. e-Pub 11/12/2010. PMID: 21076190.
37. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Purdy JA, Kuban D, Lee AK, Cheung MR, Thames HD, Cox JD. Late Rectal Toxicity on RTOG 94-06: Analysis Using a Mixture Lyman Model. Int J Radiat Oncol Biol Phys 78(4):1253-60, 11/15/2010. e-Pub 7/2/2010. PMCID: PMC2963659.
38. Meyer J, Bluett J, Amos R, Levy L, Choi S, Nguyen QN, Zhu XR, Gillin M, Lee A. Spot Scanning Proton Beam Therapy for Prostate Cancer: Treatment Planning Technique and Analysis of Consequences of Rotational and Translational Alignment Errors. Int J Radiat Oncol Biol Phys 78(2):428-34, 10/1/2010. e-Pub 1/25/2010. PMID: 20100641.
39. Archambault L, Briere TM, Pönisch F, Beaulieu L, Kuban DA, Lee A, Beddar S. Toward a real-time in vivo dosimetry system using plastic scintillation detectors. Int J Radiat Oncol Biol Phys 78(1):280-7, 9/1/2010. e-Pub 3/16/2010. PMCID: PMC2889037.
40. Frank SJ, Kudchadker RJ, Kuban DA, De Crevoisier R, Lee AK, Cheung RM, Choi S, Tucker SL, Dong L. A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol 33(2):173-5, 4/2010. PMID: 20010077.
41. Zhu XR, Sahoo N, Zhang X, Robertson D, Li H, Choi S, Lee AK, Gillin MT. Intensity modulated proton therapy treatment planning using single-field optimization: the impact of monitor unit constraints on plan quality. Med Phys 37(3):1210-9, 3/2010. PMCID: PMC2837732.
42. Lee AK, Amling CL. Appropriate use of nomograms to guide prostate cancer treatment selection. J Natl Compr Canc Netw 8(2):201-9, 2/2010. PMID: 20141677.
43. Sejpal SV, Amos RA, Bluett JB, Levy LB, Kudchadker RJ, Johnson J, Choi S, Lee AK. Dosimetric Changes Resulting From Patient Rotational Setup Errors in Proton Therapy Prostate Plans. Int J Radiat Oncol Biol Phys 75(1):40-8, 9/2009. e-Pub 12/2008. PMID: 19058919.
44. Smith A, Gillin M, Bues M, Zhu XR, Suzuki K, Mohan R, Woo S, Lee A, Komaki R, Cox J, Hiramoto K, Akiyama H, Ishida T, Sasaki T, Matsuda K. The MD Anderson Proton Therapy System. Med Phys 36(9):4068-83, 9/2009. PMID: 19810479.
45. Anderson JF, Swanson DA, Levy LB, Kuban DA, Lee AK, Kudchadker R, Phan J, Bruno T, Frank SJ. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology 74(3):601-5, 9/2009. e-Pub 7/2009. PMID: 19589580.
46. Kudchadker RJ, Lee AK, Yu ZH, Johnson JL, Zhang L, Zhang Y, Amos RA, Nakanishi H, Ochiai A, Dong L. Effectiveness of Using Fewer Implanted Fiducial Markers for Prostate Target Alignment. Int J Radiat Oncol Biol Phys 74(4):1283-9, 7/15/2009. e-Pub 5/7/2009. PMID: 19427750.
47. Arjomandy B, Sahoo N, Cox J, Lee A, Gillin M. Comparison of surface doses from spot scanning and passively scattered proton therapy beams. Phys Med Biol 54(14):N295-302, 7/2009. e-Pub 6/2009. PMID: 19550003.
48. Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys 74(2):616-22, 6/2009. PMID: 19427561.
49. Frank SJ, Levy LB, Kuban DA, Lee AK, Kudchadker RJ, Bruno TL, van Vulpen M, Swanson DA. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol 181(4). e-Pub 2/2009. PMID: 19233434.
50. Kudchadker RJ, Swanson DA, Kuban DA, Lee AK, Bruno TL, Frank SJ. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era? Int J Radiat Oncol Biol Phys 72(2):623-7, 10/1/2008. PMID: 18410998.
51. Frank SJ, Dong L, Kudchadker RJ, De Crevoisier R, Lee AK, Cheung R, Choi S, O'Daniel J, Tucker SL, Wang H, Kuban DA. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys 71(3):813-20, 7/1/2008. PMID: 18207664.
52. O'Daniel JC, Dong L, Zhang L, Wang H, Tucker SL, Kudchadker RJ, Lee AK, Cheung R, Cox JD, Kuban DA, Mohan R. Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys 71(1):274-80, 5/1/2008. PMID: 18406891.
53. Taddei PJ, Fontenot JD, Zheng Y, Mirkovic D, Lee AK, Titt U, Newhauser WD. Reducing stray radiation dose to patients receiving passively scattered proton radiotherapy for prostate cancer. Phys Med Biol 53(8):2131-47, 4/2008. PMID: 18369278.
54. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67-74, 1/1/2008. PMID: 17765406.
55. Spiess PE, Busby JE, Jordan JJ, Steinberg JR, Bassett RL, Davuluri R, Burt K, Troncoso P, Lee AK, Taylor SH, Pisters LL. Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer? Urol Oncol 26(1):25-30, Jan-Feb, 1/2008. PMID: 18190826.
56. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 11(7):1417-28, 10/2007. PMID: 17694553.
57. Zhang Y, Zhang L, Zhu XR, Lee AK, Chambers M, Dong L. Reducing metal artifacts in cone-beam CT images by preprocessing projection data. Int J Radiat Oncol Biol Phys 67(3):924-32, 3/1/2007. e-Pub 12/8/2006. PMID: 17161556.
58. Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y, Newhauser WD, Gillin M, Mohan R. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys 67(2):620-9, 2/1/2007. PMCID: PMC1945214.
59. Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K, Troncoso P, Merriman KW, Pisters LL. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 99(2):321-5, 2/2007. e-Pub 11/28/2006. PMID: 17155975.
60. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177(6):2151-6, 2007. PMID: 17509305.
61. de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, Kudchadker RJ, Newhauser WD, Zhang L, Mohan R, Dong L. Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. Int J Radiat Oncol Biol Phys 68(5):1529-36, 2007. PMID: 17544595.
62. Lee AK. Commentary on "Cancer Specific Mortality After Radiation Therapy with Short-Course Hormonal Therapy or Radical Prostatectomy in Men with Localized, Intermediate-Risk to High-Risk Prostate Cancer". The American Journal of Hematology/Oncology 6(4):19-21, 2007.
63. Zullo JR, Kudchadker R, Wu R, Lee A, Prado K. Implication of CT table sag on geometrical accuracy during virtual simulation. Med Dosim 32(4):233-6, 2007. PMID: 17980822.
64. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, Kudchadker RJ, Thames H, Mohan R, Kuban D. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67(4):1059-65, 2007. PMID: 17241755.
65. Melancon AD, O'Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, Cheung RM, de Crevoisier R, Tucker SL, Newhauser WD, Mohan R, Dong L. Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol 85(2):251-259, 2007. PMID: 17892900.
66. Newhauser W, Fontenot J, Koch N, Dong L, Lee A, Zheng Y, Waters L, Mohan R. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate. Phys Med Biol 52(11):2937-52, 2007. PMID: 17505081.
67. Lee AK, D'Amico AV. Using prostate-specific antigen doubling time in clinical practice. BJU Int 100(2):240-243, 2007. PMID: 17511769.
68. O'Daniel JC, Dong L, Zhang L, de Crevoisier R, Wang H, Lee AK, Cheung R, Tucker SL, Kudchadker RJ, Bonnen MD, Cox JD, Mohan R, Kuban DA. Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 66(3):883-91, 11/1/2006. PMID: 17011461.
69. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107(3):631-9, 8/1/2006. PMID: 16802288.
70. Lee AK, Frank SJ. Update on radiation therapy in prostate cancer. Hematol Oncol Clin North Am 20(4):857-78, 8/2006. PMID: 16861119.
71. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 107(2):275-80, 7/15/2006. PMID: 16770783.
72. Lee CT, Dong L, Ahamad AW, Choi H, Cheung R, Lee AK, Horne DF, Breaux AJ, Kuban DA. Comparison of treatment volumes and techniques in prostate cancer radiation therapy. Am J Clin Oncol 28(6):618-25, 12/2005. PMID: 16317275.
73. Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23(32):8192-7, 11/10/2005. PMID: 16278472.
74. Lee AK, Levy LB, Cheung R, Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63(2):456-62, 10/1/2005. PMID: 15927415.
75. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63(1):134-40, 9/1/2005. PMID: 16111581.
76. Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 66(2):327-31, 8/2005. PMID: 16040084.
77. Court LE, Dong L, Lee AK, Cheung R, Bonnen MD, O'Daniel J, Wang H, Mohan R, Kuban D. An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. Int J Radiat Oncol Biol Phys 62(1):154-63, 5/1/2005. PMID: 15850916.
78. Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ, Shen Y, Yang Y, Chichakli R, Pisters LL. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer 103(10):2060-6, 5/15/2005. PMID: 15822114.
79. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(4):993-1002, 3/15/2005. PMID: 15752878.
80. Wang H, Dong L, Lii MF, Lee AL, de Crevoisier R, Mohan R, Cox JD, Kuban DA, Cheung R. Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 61(3):725-35, 3/1/2005. PMID: 15708250.
81. Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(1):14-9, 1/1/2005. PMID: 15629589.

Invited Articles

1. Lee AK. Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 16(1):20-8, 1/2006. PMID: 16378903.

Abstracts

1. Lee AK, Kudchadker R, Choi B, Choi S, Bluett J, Zhu R, Dong L. The effectiveness of rectal balloon and orthogonal imaging for proton therapy of prostate cancer. Int J Radiat Oncol Biol Phys 72(1):S553-4, 2008.
2. Cheung MR, Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Kuban D, Lee AK, Cox JD. Dose-volume analyses of grade > 2 late rectal toxicity among patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 69(3):S9, 2007.
3. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Lee AK, Cheung MR, Kuban DA, Cox JD, Mohan R. Fit of a generalized lyman normal- tissue complication probability (NTCP) model to grade > 2 late rectal toxicity date from patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 69(3):S8-S9, 2007.
4. Kudchadker R, Zhu X, Zhang L, Lee A, Mohan R, Gillin M, Dong L. Implementation of on-board imager for daily image-guided radiation therapy in a multi-vendor environment. 48th AAPM Meeting, Orlando, FL, 2007.
5. Lee AK, Kudchadker RJ, Amos RA, Johnson JL, Choi SL, Kuban DA, Cox JD, Mohan R, Gillin M, Dong L. Proton Therapy vs. IMRT for prostate cancer: A dosimetric comparison. Int J Radiat Oncol Biol Phys 69(3):S342, 2007.

Book Chapters

1. Nguyen Q, Choi S, Lee AK. Proton Therapy for the Treatment of Prostate Cancer. In: Prostate Cancer, 2011.
2. Mohan R, Gillin M, Woo S, Lee A. Proton Radiotherapy. In: Textbook of Radiation Oncology: Steven A. Leibel. Elsevier- Mosby- Saunders, 2009.
3. Cox JD, Ang KK, Lee A, and Pollack A.. The Prostate. In: Radiation Oncology: Rationale, Techniques, Results, Ninth. Elsevier: United States, 2009. ISBN: ISBN-13: 978-0-323-04971-9.

Last updated: 7/22/2014